 |
|
DACH1 a key protein for tumor suppression in ER+ breast cancer
July 15, 2009(PHILADELPHIA) Researchers from the Kimmel Cancer Center at Jefferson have identified a protein relationship that may be an ideal treatment target for ER+ breast cancer. The study was reported in the July 15 issue of Cancer Research.
DACH1, a cell fate determination factor protein, prevents cancer cell proliferation by repressing the function of estrogen receptorsin breast cancer, the researchers found. However, they also found that as the presence of DACH1 decreases in breast cancer, the presence of estrogen receptors increases, and vice versa.
Approximately 70% of breast cancers are ER+. Treatment for ER+ breast cancer usually consists of hormone therapy, which includes lowering the natural estrogen levels in the body or using synthetic drugs like tamoxifen, which compete with natural estrogen. However, this treatment only works for a few years.
"Eventually, cancer cells will circumvent the estrogen-dependent growth and find a different pathway through which they will proliferate," said Vladimir Popov, a doctoral student in Biochemistry and Molecular Biology at Jefferson College of Graduate Studies of Thomas Jefferson University and the study's first author. "Our lab has shown that there is a correlation between DACH1 and estrogen receptors. DACH1 is a naturally occurring repressor of estrogen receptor function in normal breast tissue, which makes it a promising therapeutic target for patients with ER+ breast cancer."
DACH1 is expressed in normal breast tissue. As breast cancer develops and becomes more invasive, the expression of DACH1 decreases. In a previous study of more than 2,000 breast cancer patients, Jefferson researchers found that a lack of DACH1 expression was associated with a poor prognosis. Patients who did express DACH1 lived an average of 40 months longer.
"Many more studies need to be done, but there is strong evidence that DACH1 is a promising marker of survival and therapeutic target in patients with breast cancer," said the study's senior researcher Richard Pestell, M.D., Ph.D, who is director of the Kimmel Cancer Center and chair of the Cancer Biology department at Jefferson.
Thomas Jefferson University
"Eventually, cancer cells will circumvent the estrogen-dependent growth and find a different pathway through which they will proliferate," said Vladimir Popov, a doctoral student in Biochemistry and Molecular Biology at Jefferson College of Graduate Studies of Thomas Jefferson University and the study's first author. "Our lab has shown that there is a correlation between DACH1 and estrogen receptors. DACH1 is a naturally occurring repressor of estrogen receptor function in normal breast tissue, which makes it a promising therapeutic target for patients with ER+ breast cancer."
DACH1 is expressed in normal breast tissue. As breast cancer develops and becomes more invasive, the expression of DACH1 decreases. In a previous study of more than 2,000 breast cancer patients, Jefferson researchers found that a lack of DACH1 expression was associated with a poor prognosis. Patients who did express DACH1 lived an average of 40 months longer.
"Many more studies need to be done, but there is strong evidence that DACH1 is a promising marker of survival and therapeutic target in patients with breast cancer," said the study's senior researcher Richard Pestell, M.D., Ph.D, who is director of the Kimmel Cancer Center and chair of the Cancer Biology department at Jefferson.
Thomas Jefferson University
Tumor Suppression Current Events and Tumor Suppression News RSSCancer metabolism discovery uncovers new role of IDH1 gene mutation in brain cancer
Agios Pharmaceuticals today announced that its scientists have established, for the first time, that the mutated IDH1 gene has a novel enzyme activity consistent with a cancer-causing gene, or oncogene.
Baumann Lab demonstrates role of protein in distinguishing chromosome ends from DNA breaks
The Stowers Institute's Baumann Lab has demonstrated how human cells protect chromosome ends from misguided repairs that can lead to cancer.
Waste disposal protein is mechanism behind cancer tumor suppression
"Taking out the trash" takes on a whole new meaning, as investigators at The Cancer Institute of New Jersey (CINJ) and Rutgers, The State University of New Jersey, have discovered that a waste disposal protein is the key to cancer tumor suppression in a process known as autophagy.
Environmental exposures may damage DNA in as few as 3 days
Exposure to particulate matter has been recognized as a contributing factor to lung cancer development for some time, but a new study indicates inhalation of certain particulates can actually cause some genes to become reprogrammed, affecting both the development and the outcome of cancers and other diseases.
Researchers Identify Specific Lung Cancer Susceptibility Gene
University of Cincinnati (UC) cancer cell biologists have identified a distinct gene linked to increased lung cancer susceptibility and development.
New radiation-free targeted therapy detects and eliminates breast cancer tumors in mice
Combining a compound known as a gallium corrole with a protein carrier results in a targeted cancer therapy that is able to detect and eliminate tumors in mice with seemingly fewer side effects than other breast-cancer treatments, says a team of researchers from the California Institute of Technology (Caltech), the Israel Institute of Technology (Technion) and the Cedars-Sinai Medical Center.
Genetic breakdown in Fanconi anemia may have link to HPV-associated cancer
A genetic malfunction that causes DNA instability in people with the blood disorder Fanconi anemia may put them at high risk for squamous cell carcinomas linked to human papillomavirus (HPV), according to a study posted online ahead of print by Oncogene.
Molecular basis for neurodegeneration in Ataxia telangiectasia
An upcoming paper from Dr. David Wassarman (University of Wisconsin School of Medicine and Public Health) in the May 1 issue of G&D lends new insight into the pathogenesis of neurodegeneration in Ataxia telangiectasia.
Oncoproteins double-team and destroy vital tumor-suppressor
Two previously unconnected cancer-promoting proteins team up to ambush a critical tumor suppressor by evicting it from the cell's nucleus and then marking it for death by a protein-shredding mechanism, a team led by scientists at The University of Texas M. D. Anderson Cancer Center reports in the Feb. 10 issue of Nature Cell Biology.
CSHL scientists identify and repress breast cancer stem cells in mouse tissue
By manipulating highly specific gene-regulating molecules called microRNAs, scientists at Cold Spring Harbor Laboratory (CSHL) report that they have succeeded in singling out and repressing stem-like cells in mouse breast tissue - cells that are widely thought to give rise to cancer.
More Tumor Suppression Current Events and Tumor Suppression News Articles
|
Lorus obtains United States tumor suppression patent.(Lorus Therapeutics)(Brief Article): An article from: BIOTECH Patent News by Biotech Patent News (Publisher) This digital document is an article from BIOTECH Patent News, published by Biotech Patent News on May 1, 2002. The length of the article is 456 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser. Citation Details Title: Lorus obtains United States tumor suppression patent.(Lorus Therapeutics)(Brief Article) Publication: BIOTECH Patent News (Newsletter) Date: May 1, 2002 Publisher: Biotech Patent News Volume: 16 Issue: 5 Page: NA Article Type: Brief Article Distributed by Thomson... | |
 |
Cellular Senescence and Tumor Suppression by Peter D. Adams (Editor), John M. Sedivy (Editor) As cells mature they naturally stop dividing and enter a period called senescence. But cellular senescence can also be induced prematurely by certain oncogenes involved in cancer development. Cellular senescence, a growth-arrest program that limits the lifespan of mammalian cells and prevents unlimited cell proliferation, is attracting considerable interest because of its links to tumor suppression. |
|
GENETICS: TUMOR SUPPRESSION: An entry from Macmillan Reference USA's Encyclopedia of Aging by JUDITH CAMPISI (Author) As the Baby Boomers head toward retirement, the four-volume “Encyclopedia of Aging” offers a timely resource encompassing all aspects of aging. Covering a variety of disciplines—biology, medicine, economics, law, psychology, sociology and history—the Encyclopedia also explores related issues such as religion, spirituality, and ethics. | |
|
Recessive Oncogenes and Tumor Suppression (Current Communications in Cell and Molecular Biology) by Webster Cavenee (Author), Nicholas Hastie (Author), Eric Stanbridge (Editor) | |
 |
Tumor-Induced Immune Suppression: Mechanisms and Therapeutic Reversal by Dmitry I. Gabrilovich (Editor), Andy Hurwitz (Editor) There is now a pressing need to discuss the already described and newly emerging mechanisms to see how they can be put together in more or less cohesive structure and how they can help to improve immune response to tumors. This monograph will, for the first time, present a comprehensive overview of different mechanisms of immune dysfunction in cancer as well as therapeutic approaches to their correction. It will discuss a number of new mechanisms that have never been discussed in a monograph before: T-cell inhibitory molecules, regulatory tolerogenic DCs, and signaling pathways in antigen-presenting cells involved in T-cell tolerance. |
 |
Cancer Immunotherapy: Immune Suppression and Tumor Growth by George C. Prendergast (Editor), Elizabeth M. Jaffee (Editor) There has been major growth in understanding immune suppression mechanisms and its relationship to cancer progression and therapy. This book highlights emerging new principles of immune suppression that drive cancer and it offers radically new ideas about how therapy can be improved by attacking these principles. Following work that firmly establishes immune escape as an essential trait of cancer, recent studies have now defined specific mechanisms of tumoral immune suppression. It also demonstrates how attacking tumors with molecular targeted therapeutics or traditional chemotherapeutic drugs can produce potent anti-tumor effects in preclinical models. This book provides basic, translational, and clinical cancer researchers an indispensable overview of immune escape as a critical trait... |
 |
Genetic Analysis of Tumour Suppression - Symposium No. 142 by CIBA Foundation Symposium (Author) Comprises the proceedings of a symposium held at the Ciba Foundation, London, February 1988. Contains the latest research results on the inverse relationship between cell proliferation and differentiation and the nature of the genes involved. Included are the studies of cell fusion experiments, the introduction of single chromosomes into malignant cells, and the transfection of individual genes. Also reports on the role of certain oncogenes in normal development, lineage commitment, and tumorigenesis. |
|
Tumor Suppressor Genes (Immunology Series) by George Klein (Editor) |
| © 2009 BrightSurf.com |